publications

2019-2020

  1. Liu YC, Chiang IT, Chung JG, Hsieh JH, Chiang CH, Weng MC, Hsu FT*, Lee YH*, Chang CS*, Lin SS* (2020): Therapeutic efficacy and inhibitory mechanism of regorafenib combined with radiation in colorectal cancer. (In Vivo accepted 2020.08)

  2. Liu YC, Tsai JJ, YS Weng, Hsu FT* (2020). Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer. Biomedicine & Pharmacotherapy, 128:110319.

  3. Su CM, Weng YS, Kuan LY, Hsu FT* (2020). Suppression of PKCδ/NF-κB activation and apoptosis induction through extrinsic/intrinsic pathways are associated magnolol-inhibited tumor progression in colorectal cancer in vitro and in vivo. International Journal of Molecular Sciences 21(10), 3527; https://doi.org/10.3390/ijms21103527. (*corresponding author)

  4. Hsu FT, Chen WT, Wu CT, Chung JG: Hyperforin induces apoptosis through extrinsic/intrinsic pathways and inhibits EGFR/ERK/NF-κB-mediated anti-apoptotic potential in glioblastoma. Environmental toxicology doi: 10.1002/tox.22942.

  5. Chen YS, SUN R, Chen WL, Yao YC, Hsu FT, Chung JG, Tsai CJ, Hsieh CL, Chiu YM and Chen JH (2020): The In Vivo Radiosensitizing Effect of Magnolol on Tumor Growth of Hepatocellular Carcinoma. In Vivo 34(4):1789-1796.

  6. Hsu LC, Tu HF, Hsu FT, Yueh PF, Chiang IT (2020): Beneficial effect of fluoxetine on anti-tumor growth on hepatocellular carcinoma and non-small cell lung cancer bearing animal model. Biomedicine & Pharmacotherapy, 126:110054. doi: 10.1016/j.biopha.2020.110054..

  7. Hsu FT, Chiang IT, Wang WS (2020): Induction of apoptosis through extrinsic/intrinsic pathways and suppression of ERK/NF-κB signaling participate in the imipramine-inhibited progression of glioblastoma. Journal of Cellular and Molecular Medicine 24(7):3982-4000, https://doi.org/10.1111/jcmm.15022.

  8. Tsai JJ, Pan PJ, Hsu FT*, Chung JG, Chiang IT (2020): Glycyrrhizic acid modulates apoptosis through extrinsic/intrinsic pathways and inhibits protein kinase B- and extracellular signal-regulated kinase-mediated metastatic potential in hepatocellular carcinoma in vitro and in vivo. American Journal of Chinese Medicine 48(1):223-244, doi: 10.1142/S0192415X20500123. (*co-corresponding author)

  9. Su CM, Wang HC, Hsu FT, Lu CH, Lai CK, Chung JG, Kuo YC (2019): Astragaloside IV induces apoptosis, G1 phase arrest and inhibits anti-apoptotic signaling in hepatocellular carcinoma. In Vivo 34(2): 631–638.

  10. Chen JH, Chiang IT, Hsu FT* (2019): Protein kinase B inactivation was associated with magnolol-enhanced therapeutic efficacy of sorafenib in hepatocellular carcinoma in vitro and in vivo. Cancers 2020, 12(1), 87. (*co-corresponding author)

  11. Tsai JJ, Chen JH, Chen CH, Chung JG, Hsu FT* (2019): Apoptosis induction and suppression of ERK/NF-κB activation are associated with magnolol-inhibited tumor progression in hepatocellular carcinoma in vivoEnvironmental toxicology (2019.08 accepted) (*co-corresponding author)

  12. Liu YC, Lin KH, Hsieh JH, Chung JG, Tan ZL , Hsu FT, Chiang CH (2019): Hyperforin induces apoptosis through extrinsic/intrinsic pathways and inhibits NF-κB-modulated survival and invasion potential in bladder cancer. In Vivo 33(6): 1865–1877.

  13. PJ Pan, YC Liu*, Hsu FT* (2019): Protein kinase B and extracellular signal-regulated kinase inactivation is required for regorafenib-induced inhibition of osteosarcoma progression in vitro and in vivo. Journal of Clinical Medicine 8(6). pii: E900. doi: 10.3390/jcm8060900. (*co-corresponding author)

  14. Wang MC, Li MH, Chung JG, Liu YC, Wu JY, Hsu FT*, Wang HE* (2019): Apoptosis induction and AKT/NF-κB inactivation are associated with regorafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo. Biomedicine & Pharmacotherapy. 116, 109032 (*co-corresponding author)

  15. Lee YJ, Chung JG, Chien YT, Lin SS, Hsu FT* (2019). Suppression of ERK/NF-κB activation is associated with amentoflavone-inhibited osteosarcoma progression in vivo. Anticancer Research 39: 3669-3675 (*co-corresponding author)

  16. Hsu FT, Chiang IT, Kuo YC, Liu YC*, Chung JG* (2019): Amentoflavone effectively blocked glioblastoma tumor progression via suppression of ERK/NF-κB signaling pathway. American Journal of Chinese Medicine 47(4):913-931. doi: 10.1142/S0192415X19500484. (first author)

  17. Hsu FT, Rou Sun and Chia-Ling Hsieh (2019): Cellular Magnetic Resonance Imaging with Superparamagnetic Iron Oxide: Methods and Application in Cancer. SPIN, https://doi.org/10.1142/S2010324719400071 (first author)

  18. Chen WT, Hsu FT, Liu YC, Chen CH, Hsu LC, Lin SS (2019): Fluoxetine induces apoptosis through extrinsic/intrinsic pathways and inhibits ERK/NF-κB-modulated anti-apoptotic and invasive potential in hepatocellular carcinoma cells in vitro. International Journal of Molecular Sciences 20(3), 757

  19. Chiang CH, Chung JG*, Hsu FT* (2019): Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF-κB-modulated tumor progression in bladder cancer in vitro and in vivo. Environmental toxicology 34(6):679-688 doi: 10.1002/tox.22734. (*co-corresponding author)

  20. Chen CH, Chuang HY, Liao YJ, Hsu FT, Chen YC, Wang WH, Hwang JJ (2019): Enhanced cytotoxicity of human hepatocellular carcinoma cells following pretreatment with sorafenib combined with trichostatin A. Oncology Letters 17(1):638-645.

2018

  1. Kuan LY, Chen WL, Chen JH, Hsu FT, Liu TT, Chen WT, Wang KL, Chen WC, Liu YC and Wang WS (2018): Magnolol Induces Apoptosis and Inhibits ERK-modulated Metastatic Potential in Hepatocellular Carcinoma Cells. In Vivo 32(6):1361-1368.

  2. Wu JY, Lin SS*, Hsu FT*, Chung JG (2018): Fluoxetine Inhibits DNA Repair and NF-κB-modulated Metastatic Potential in Non-small Cell Lung Cancer. Anticancer Research 38(9):5201-5210. (*co-corresponding author)

  3. Chou YC, Chang MY, Lee HT, Shen CC, Harnod T, Liang YJ, Wu RS, Lai KC, Hsu FT*, Chung JG*. Phenethyl Isothiocyanate Inhibits In Vivo Growth of Xenograft Tumors of Human Glioblastoma Cells. Molecules 23(9). pii: E2305. doi: 10.3390/molecules23092305. (*co-corresponding author)

  4. Hsu FT, Wei ZH, Hsuan CY, Lin W, Su YC, Liao CH, Hsieh CL (2018): MRI tracking of polyethylene glycol–coated superparamagnetic iron oxide-labeled placenta-derived mesenchymal stem cells toward glioblastoma stem-like cells in a mouse model. Artificial Cells, Nanomedicine, and Biotechnology; 46(sup3):S448-S459. doi: 10.1080/21691401.2018.1499661.

  5. Lee KC, Chen WT, Liu YC, Lin SS*, Hsu FT* (2018): Amentoflavone inhibits hepatocellular carcinoma progression through blockage of ERK/NF-κB activation. In Vivo 32(3): 549–554. (*co-corresponding author)

  6. Ma YS, Lin JJ, Lin CC, Lien JC, Peng SF, Hsu FT*, and Chung JG* (2018): Benzyl Isothiocyanate (BITC) Inhibits Human Brain Glioblastoma Multiforme GBM 8401 Cell Xenograft Tumor in Nude Mice In Vivo. Environmental Toxicology 33(11):1097-1104 doi: 10.1002/tox.22581. (*co-corresponding author)

  7. Chang Y*, Chen CJ*, Hsu FT, Tseng YC, Kung KL, Huang TC (2018): Calculation of Bone Calcium Hydroxyapatite Concentration Using Abdomen Gemstone Spectral Imaging Computed Tomography in Taiwan. Journal of Medical Imaging and Health Informatics 8(6):1217-1225.

  8. Weng MC, Wang MH, Tsai JJ, Kuo YC, Liu YC, Hsu FT*, Wang HE* (2018): Regorafenib inhibits tumor progression through suppression of ERK/NF-kB activation in hepatocellular carcinoma bearing mice. Bioscience Reports pii: BSR20171264. doi: 10.1042/BSR20171264. (*co-corresponding author)

  9. Lee KC, Tsai JJ, Tseng CW, Kuo YC, Chuang YC, Lin SS* and Hsu FT* (2018): Amentoflavone Inhibits ERK-Modulated Tumor Progression in Hepatocellular Carcinoma In Vitro. In Vivo 32(3):549-554. (*corresponding author)

  10. Lin CY, Yang ST, Shen SC, Hsieh YC, Hsu FT, Chen CY, Chiang YH, Chuang JY, Chen KY, Hsu TI, Leong WC, Su YK, Lo WL, Yeh YS, Patria YN, Shih HM, Chang CC, Chou SY (2018).  Serum amyloid A1 (SAA1) coordinating with integrin αVβ3 increases glioblastoma cells mobility and progression. Molecular Oncology 12(5):756-771

  11. Chen WT, Chen YK*, Lin SS*, Hsu FT* (2018): Hyperforin Suppresses Tumor Growth and NF-kB-Mediated Anti-apoptotic and Invasive Potential of Non-Small Cell Lung Cancer. Anticancer Research 38(4):2161-2167. (*corresponding author)

  12. Tsai JJ, Hsu FT, Pan PJ, Chen CW, Kuo YC (2018): Amentoflavone Enhances Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo. Anticancer Research 38(4):2119-2125.

  13. Hsu FT, Liu HS, Ahmed AA, Tsai PH, Kao YC, Lu CF, Huang SH, Chen CY (2018): Assessing the Selective Therapeutic Efficacy of Superparamagnetic Erlotinib Nanoparticles in Lung Cancer by Using Quantitative Magnetic Resonance Imaging and a Nuclear Factor Kappa-B Reporter Gene System. Nanomedicine 14(3):1019-1031.  (first author)

  14. Liu HS, Chiang SW, Chung HW, Tsai PH, Hsu FT, Nai-Yu Cho NY, Wang CY, Chou MC, Chen CY (2018): Histogram analysis of T2*-based pharmacokinetic imaging in cerebral glioma grading. Computer Methods and Programs in Biomedicine 155, 19-27.

  15. Yen TH, Hsieh CL, Liu TT, Huang CS, Chen YC, Chuang YC, Lin SS, Hsu FT* (2018): Amentoflavone Induces Apoptosis and Inhibits NF-kappaB-Modulated Anti-apoptotic signaling in Glioblastoma Cells. In Vivo 32(2): 279-285. (*corresponding author)

2009-2017

  1. Chen HL, Hsu FT, Kao YC, Liu HS, Huang WZ, Lu CF, Tsai PH, Lee G, Ahmed AA, Chen RJ, Chen CY (2017): Identification of epidermal growth factor receptor-positive glioblastoma using lipid-encapsulated targeted superparamagnetic iron oxide nanoparticles in vitro. Journal of Nanobiotechnology 15(1):86.

  2. Hsu FT, Sun CC, Wu CH, Lee YJ, Chiang CH, Wang WS (2017): Regorafenib induces apoptosis and inhibits metastatic potential in human bladder carcinoma cells. Anticancer Research 37(9):4919-4926. (first author)

  3. Tsai JJ, Pan PJ, Hsu FT* (2017): Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells. Oncology Reports 37(2):1036-1044. (*corresponding author)

  4. Chen WL, Hsieh CL, Chen JH, Huang CS, Chen WT, Kuo YC, Chen CY, Hsu FT* (2017): Amentoflavone enhances sorafenib-induced apoptosis through both extrinsic and intrinsic pathways in sorafenib resistant hepatocellular carcinoma SK-Hep1 cells in vitro. Oncology Letters 14(3):3229-3234. (*corresponding author)

  5. Chen JC*, Chuang HY*, Hsu FT*Chen YCChien YCHwang JJ (2016): Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model. Oncotarget 7(51): 85450–85463 doi: 10.18632/oncotarget.13398. (*co-first author)

  6. Ali AA, Hsu FT, Hsieh CL, Shiau CY, Chiang CH, Wei ZH, Chen CY, Huang HS (2016): Erlotinib-Conjugated Iron Oxide Nanoparticles as a Smart Cancer-Targeted Theranostic Probe for MRI. Scientific Reports 11;6:36650.

  7. Lin YL, Chen CH, Wu HY, Tsai NM, Jain TY, Chang YC, Lin CH, Wu CH, Hsu FT, Leung TK, Liao KW (2016): Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex. Journal of Nanobiotechnology 19; 14(1):11.

  8. Hsu FT, Chen TZ, Chuang HY, Chang YF, Hwang JJ (2015): Therapeutic Enhancement of Adoptive T Cell Transfer with One Low-Dose Doxorubicin or Paclitaxel through Inhibition of NF-kB and Modulation of Immune Functions. Oncotarget 29;6(42):44134-50. (first author)

  9. Hsu FT, Liu YC, Hwang JJ (2015): Curcumin Sensitizes Hepatocellular Carcinoma Cells to Radiation via Suppression of Radiation-Induced NF-kB Activity. BioMed Research International 11; 2015:363671. (first author)

  10. Hsu FT, Chang B, Chen CH, Chiang IT, Liu YC, Hwang JJ (2015): Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo. Scientific Reports 21; 5:15391. (first author)

  11. Su YC, Yu CC, Hsu FT, Fu SL, Hwang JJ, Hung LC, Lee MS, Chiou WY, Lin HY, Hung SK (2014): Everolimus sensitizes Ras-transformed cells to radiation in vitro through the autophagy pathway. International Journal of Molecular Medicine 34(5):1417-22.

  12. Hsu FT, Chang B, Chiang IT, Wu TS, Hwang JJ (2014): Synergistic Effect of Sorafenib with Ionizing Radiation on Human Oral Cancer Cells. In Vivo 28(5):925-33. (first author)

  13. Hsu FT, Liu YC, Chiang IT, Liu RS, Wang HE, Lin WJ, Hwang JJ (2014): Sorafenib Increases Efficacy of Vorinostat against Human Hepatocellular Carcinoma through Inhibition of Vorinostat-induced ERK/NF-κB Signaling Transduction. International Journal of Oncology 45(1): 177-188. (first author)

  14. Chiang IT*, Liu YC*, Hsu FT*, Chien YC, Kao CH, Lin WJ, Chung JG, Hwang JJ (2014): Curcumin synergistically enhances the radiosensitivity of human oral squamous cell carcinoma via suppression of radiation-induced NF-κB activity. Oncology Reports 31(4): 1729-1737. (*co-first author)

  15. Wang WH, Chiang IT, Liu YC, Hsu FT, Chen HW, Chen CL, Lee YJ, Lin WJ, Hwang JJ (2013): Simultaneous imaging of temporal changes of NF-κB activity and viable tumor cells in Huh7/NF-κB-tk-luc2/rfp tumor-bearing mice. In Vivo 27(3): 339-350.

  16. Chen HW*, Hsu FT*, Chang YC, Tu HF, Fang CK, Kuo SP, and Hwang JJ (2013): Hypoxanthine-guanine phosphoribosyl-transferase gene mutation in oral cancer patients treated with radiography. Adaptive Medicine 5(2): 83-91 (*co-first author) 

  17. Chiang IT, Liu YC, Wang WH, Hsu FT, Chen HW, Lin WJ, Chang WY, Hwang JJ (2012): Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-κB pathway in hepatocellular carcinoma cells. In Vivo 26(4): 671-681.

  18. Liu YC, Chiang IT, Hsu FT and Hwang JJ (2012): Using NF-kB as a molecular target for theranostics in radiation oncology research. Expert Review Molecular Diagnostics. 12(2): 139-146.

  19. Chen JH, Nie K, Bahri S, Hsu CC, Hsu FT, Shih HN, Lin M, Nalcioglu O, Su MY (2010): Decrease in Breast Density in the Contralateral Normal Breast of Patients Receiving Neoadjuvant Chemotherapy: MR Imaging Evaluation. Radiology 255: 44-52.

  20. Chen JH, Hsu FT, Shih HN, Hsu CC, Chang D, Nie K, Nalcioglu O, Su MY (2009): Comparison of breast density in the contralateral normal breast of patients with invasive and in situ breast cancer measured on MRI. Annals of Oncology 20: 1440-1450.

  21. Chen JH, Hsu FT, Shih HN, Hsu CC, Chang D, Nie K, Nalcioglu O, Su MY (2009): Does breast density show difference in patients with estrogen receptor-positive and estrogen receptor-negative breast cancer measured on MRI. Annals of Oncology 20: 1447-1449.

  • Google+ - Black Circle

© 2018 by FTH. Proudly created with Wix.com

Follow me on social netwroks

This site was designed with the
.com
website builder. Create your website today.
Start Now